Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study

ConclusionDARA is an effective treatment option for most patients and is tolerable. However, patients with heavy treatment before DARA therapy and mass lesions are likely to show poorer outcomes. Our findings suggest the use of DARA therapy early in the course of the disease.

http://link.springer.com/10.1007/s10147-020-01754-2

Source: International Journal of Clinical Oncology - July 25, 2020 Category: Cancer & Oncology Source Type: research